Completed OBSERVATIONAL NCT03566966

Autoantibodies and Direct-acting Antivirals (BIOEPA)

Clinical Relevance of Serum Non-organ-specific Antibodies in Hepatitis C Virus Patients Receiving Direct-acting Antiviral Therapy

Sponsor: University of Bari

Conditions Therapy Adverse Effect Viral Hepatitis C

Interventions Non-organ-specific Ab negative Non-organ-specific Ab positive

Updated 7 times since 2018 Last updated: Dec 2, 2023 Started: Jul 1, 2015 Primary completion: Aug 31, 2016 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03566966, this observational or N/A phase trial focuses on Therapy Adverse Effect and Viral Hepatitis C and remains completed. Sponsored by University of Bari, it has been updated 7 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2024 — Jul 2024 [monthly]

Completed
Dec 2021 — Jan 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Completed
Jul 2018 — Nov 2020 [monthly]

Completed

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Bari

Data source: University of Bari

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bari, Italy